Stryker, Smith & Nephew, Zimmer Biomet & more — 16 key notes

Here are 16 key notes on orthopedic and spine device companies over the past week.

Advertisement

EOS imaging announced the first installation of its EOS system in Saudi Arabia.

 
Exactech reported revenue was down 3 percent in the third quarter of 2015.

 

Implanet reported third quarter revenue was up 42 percent in 2015.

 

Nextremity Solutions acquired foot fusion technology from Del Palma Orthopedics.

 
NuVasive reported its third quarter 2015 financial results ending on Sept. 30, 2015 — NuVasive’s revenue increased to $200.5 million.

 

NuVasive shares dropped 4.88 percent during the past week.

 
OrthoGrid Systems developed the HipGrid Drone, a non-invasive fluoroscopic guide for total hip replacements.

 
Regenexx announced the issuance of a United States patent for its proprietary same-day stem cell procedure.

 
ReVivo Medical, an Albany, N.Y.-based biomedical startup, received a $225,000 grant.

 

RTI Surgical reported third quarter revenues were up 3 percent over the same period last year.

 

RTI Surgical added Christopher R. Sweeney and Thomas A. McEachin to the company’s board of directors.

 
Zacks also downgraded RTI Surgical from a “buy” rating to a “hold” rating.

 

Smith & Nephew agreed to acquire Blue Belt Technologies for $275 million.

 
Ronda Stryker, director at Stryker, sold 12,000 shares of the company.

 
Brean Capital gave Xtant Medical a “buy” rating and $10 price target.

 
Zimmer Biomet reported net sales were up 59.3 percent to $1.76 billion for the third quarter of 2015, shortly after the merger was completed.

 

 

 

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.